Private equity firm Permira is leading the deal, with support from General Atlantic and Accel
Uncertainty regarding impact of ruling over work sampled in artist Flo Rida’s music as it relies on a “discovery rule” that could be invalidated in future cases
Stephanie Culpepper replaces Jim Henson, who will focus on his role as president of Lument Finance Trust
New AI practice will be co-led by partners Nader Mousavi, Mehdi Ansari and Presley Warner
Scott Schirick joins in New York where he will focus on federal and state litigation, regulatory and white collar matters
Colleen Batcheler to take legal head role, which has been vacant since Lori Marco left in October
Adam Cohen and Mark Chorazak join in New York and Washington DC respectively amid increasing US bank regulation
Andrew Johnson joins from 3D Systems, replacing outgoing GC Brian Heller
Foster Garvey lawyers Kevin Frisch and Erika Johnson discuss insights from the recent SuperYacht Law Summit and other trends affecting the luxury yacht market
Chad Ho is replacing long-time legal chief Stacey Goff, who is exiting after 26 years with the company
M&A partner Maria-Leticia Ossa Daza joins in New York having founded and led Willkie’s LatAm practice
Led by respected life sciences litigator Siegmund Gutman, the team of 10 move over from Proskauer Rose
Jeff Novota will replace Mark Shaw, who is moving to an advisor role after almost 24 years as CLO
Announcement of former Shearman tax partner’s arrival came on day A&O Shearman came into being
Düsseldorf local division orders US life sciences company Curio Bioscience to stop selling its products in Germany, France and Sweden in dispute with rival 10x Genomics
David Weintraub will replace Michael Solender at the Big Four firm in July
Group includes 13 partners including Frank Segall and Josef Volman, who will co-chair new office
Kenneth Burdon to be joined by Simpson Thacher funds partner Nathan Somogie for launch later this year
Transatlantic merger creates global giant with nearly 4,000 lawyers and $3.5bn revenue
UK pharmaceutical firm enters the fray in the battle over mRNA technology used to develop blockbuster vaccines